Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 7, 2013 - Issue 2
Submit an article Journal homepage
53
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Inducing remission of ulcerative colitis: are clinicians better equipped than ever?

Alessandro Armuzzi IBD Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy. [email protected]
&
Carla Felice IBD Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy
Pages 95-97 | Published online: 10 Jan 2014

References

  • Solberg IC, Lygren I, Jahnsen J et al.; IBSEN Study Group. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand. J. Gastroenterol. 44(4), 431–440 (2009).
  • Travis SP, Higgins PD, Orchard T et al. Review article: defining remission in ulcerative colitis. Aliment. Pharmacol. Ther. 34(2), 113–124 (2011).
  • Jess T, Riis L, Vind I et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm. Bowel Dis. 13(4), 481–489 (2007).
  • Feagan BG, MacDonald JK. Oral 5-aminosalycilic acid for induction of remission in ulcerative colitis (review). Cochrane Database Syst. Rev. 10, CD000543 (2012).
  • Feagan BG, MacDonald JK. Oral 5-aminosalycilic acid for maintenance of remission in ulcerative colitis (review). Cochrane Database Syst. Rev. 10, CD000544 (2012).
  • Ford AC, Khan KJ, Achkar JP, Moayyedi P. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am. J. Gastroenterol. 107(2), 167–176; author reply 177 (2012).
  • Dignass A, Lindsay JO, Sturm A et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: current management. J. Crohns Colitis. 6(10), 991–1030 (2012).
  • Garcia-Planella E, Mañosa M, Van Domselaar M et al. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. Dig. Liver Dis. 44(3), 206–210 (2012).
  • Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 9, CD000478 (2012).
  • Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462–2476 (2005).
  • Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142(2), 257–265.e1 (2012).
  • Rutgeerts JP, Feagan BG, Marano C et al. A Phase 2/3 randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of subcutaneous golimumab induction therapy in patients with moderately to severely active ulcerative colitis: PURSUIT SC. Gut 61(Suppl. 3), A78 (2012).
  • Rutgeerts PJ, Fedorak RN, Hommes DW et al. A randomised Phase I study of etrolizumab (rhuMAb b7) in moderate to severe ulcerative colitis. Gut doi:10.1136/gutjnl-2011-301769 (2012) (Epub ahead of print).
  • Sandborn WJ, Ghosh S, Panes J et al. Tofacitib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Eng. J. Med. 367(7), 616–624 (2012).
  • Ochsenkühn T, D’Haens G. Current misunderstandings in the management of ulcerative colitis. Gut 60(9), 1294–1299 (2011).
  • Peyrin-Biroulet L, Ferrante M, Magro F et al. Result from the 2nd Scientific Workshop of the ECCO (I): impact of mucosal healing on the course of inflammatory bowel disease. J. Crohns Colitis 5, 477–483 (2011).
  • Armuzzi A, Van Assche G, Reinisch W et al. Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. J. Crohns. Colitis 6(4), 492–502 (2012).
  • Römkens TE, Kampschreur MT, Drenth JP, van Oijen MG, de Jong DJ. High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials. Inflamm. Bowel Dis. 18(11), 2190–2198 (2012).
  • Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141(4), 1194–1201 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.